GFA
PRAX icon

Gallagher Fiduciary Advisors’s Praxis Precision Medicines PRAX Stock Holding History

Gallagher Fiduciary Advisors’s Portfolio PRAX Stock Details PRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$320K Sell
957
-33
-3% -$10.4K 0.01% 283
2026
Q1 		$319K Buy
+990
New +$306K 0.01% 262

Other funds holding PRAX

JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Gallagher Fiduciary Advisors's PRAX Position: Q2 2026 in Review

Gallagher Fiduciary Advisors reduced its Praxis Precision Medicines (PRAX) stake by 3.3% in Q2 2026, selling an estimated $10.4K and leaving 957 shares worth $320K. The position accounts for 0.01% of the portfolio, ranked #283.

Gallagher Fiduciary Advisors first reported a position in PRAX in Q1 2026 and has held it in 2 quarters since. 309 funds tracked by Wall St. Rank hold PRAX as of Q2 2026.

  • Gallagher Fiduciary Advisors held 957 shares of Praxis Precision Medicines worth $320K as of Q2 2026.
  • Gallagher Fiduciary Advisors sold 33 Praxis Precision Medicines shares in Q2 2026, an estimated $10.4K.
  • Praxis Precision Medicines made up 0.01% of Gallagher Fiduciary Advisors's portfolio in Q2 2026, its #283 holding.
  • Gallagher Fiduciary Advisors first reported a position in Praxis Precision Medicines in Q1 2026 and has held it in 2 quarters since.
  • 309 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q2 2026.

Based on Gallagher Fiduciary Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.